Stockhub

Infant Bacterial Therapeutics AB

Revision as of 13:28, 21 August 2022 by >Nick (Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Summary[1] edit edit source

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent or treat rare diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, to prevent necrotizing enterocolitis, as well as to improve feeding tolerance affecting premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe disease in infants. The company was founded in 2013 and is based in Stockholm, Sweden.

References and notes edit edit source

  1. ↑ Source: Yahoo Finance.
Retrieved from "https://stockhub.co/index.php?title=Infant_Bacterial_Therapeutics_AB&oldid=56623"